Somatostatin: A hormone for the heart?

Current Vascular Pharmacology

Volumn 3, Issue 2, 2005, Pages 125-131

  Badway, Amy C ^a   Blake, Allan D ^a  

^a SETON HALL UNIVERSITY   (United States)

Author keywords

Endothelium; Inflammation; Proliferation; Somatostatin; Somatostatin analogs; Somatostatin receptors; Vasculature

Indexed keywords

ADENYLATE CYCLASE; ALBUMIN; ANGIOPEPTIN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; GLUCAGON; GROWTH HORMONE; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 10; LONG ACTING DRUG; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OCTREOTIDE; PLATELET DERIVED GROWTH FACTOR; PRL 2486; PROTEIN TYROSINE PHOSPHATASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACROMEGALY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD VESSEL FUNCTION; BLOOD VESSEL INJURY; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENDOTHELIUM; HEART VENTRICLE HYPERTROPHY; HORMONE ACTION; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; SMOOTH MUSCLE; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM;

ANIMALS; HORMONE ANTAGONISTS; HUMANS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 18044396523     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161053586958     Document Type: Review

References (97)

1. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-9.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Lefkowitz RJ, Willerson WT. Prospects for cardiovascular research. JAMA 2001; 285: 581-7.
4. Libby P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vascul Med 1998; 3: 225-9.
5. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-41.
6. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol 2001; 70: 317-25.
7. Mendelsohn ME, Karas RE. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.
8. Agro A, Stanisz AM. Are lymphocytes a target for Substance P modulation in arthritis? Sem Arthrit Rheum 1992; 21: 252-8.
9. Crofford LJ, Sano H, Karalis K, Webster EL, Goldmuntz EA, Chrousos GP, et al. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest 1992; 90: 2555-64.
10. Karalis K, Mastorakos G, Sano H, Wilder RL, Chrousos GP. Somatostatin may participate in the anti-inflammatory actions of glucocorticoids. Endocrinology 1995; 136: 4133-8.
11. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
12. Reisine T. Somatostatin receptors. Am J Physiol 1995a; 269: G813-20.
13. Krantic S. Peptides as regulators of the immune system: emphasis on somatostatin. Peptides 2000; 21: 1941-64.
14. Singh G, Liapakis G, Reisine T. Somatostatin receptor subtypes and regulation of growth hormone secretion. In: Smith RG, Thorner MO Eds, Human Growth Hormone: Research and Clinical Practice. NJ USA, Humana Press Inc 2000; 109-17.
15. Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagons secretion via two receptors subtypes: an in vivo study of pancreatic islets from somatostatin 2 knockout mice. Endocrinology 2000; 141: 111-7.
16. Larsson LN, Goltermann N, de Magistris L, Rehfeld JF, Schwartz TW. Somatostatin cell processes as pathways for paracrine secretion. Science 1979; 205: 1393-5.
17. Lloyd KC, Amirmoazzami S, Friedik F, Chew P, Walsh JH. Somatostatin inhibits gastrin release and acid secretion by activating sst2 in dogs. Am J Physiol 1997; 272: G1481-8.
18. Bhathena SJ, Louie J, Schechter GP, Redman RS, Wahl L, Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981; 30: 127-31.
19. Ghirlanda G, Zeppilli P, Uccioli L, Aspromonte N, Cotroneo P, Greco AV. Somatostatin and the cardiovascular system: experiences and prospective use. G Ital Cardiol 1985; 15: 218-23.
20. Dasgupta P. Somatostatin analogs: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004; 102: 61-85.
21. Badway AC, West FM, Tente SM, Blake AD. Somatostatin regulates intracellular signaling in human carotid endothelial cells. Biochem Biophys Res Comm 2004; 319: 1222-7.
22. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1556-63.
23. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-98.
24. de Lecea L, Criado JR, Prospero-Garcia O, Gautvik KM, Schweitzer P, Danielson PE, et al. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 1996; 381: 242-5.
25. Papotti M, Tarabra E, Allia E, Bozzalla-Cassione F, Broglio F, Deghenghi R, et al. Presence of cortistatin in the human pancreas. J Endocrinol Invest 2003; 26: RC15-8.
26. Dalm VA, van Hagen PM, van Koetsveld PM, Achilefu S, Houtsmuller AB, Pols DH, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab 2003; 285: E344-53.
27. Cassoni P, Muccioli G, Marrocco T, Volante M, Allia E, Ghigo E, et al. Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin. J Endocrinol Invest 2002; 25: 362-8.
28. Broglio F, Arvat E, Benso A, Gottero C, Prodam F, Grottoli S, et al. Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. J Clin Endocrinol Metab 2002; 87: 3783-90.
29. Reisine T. Molecular properties of somatostatin receptors. Neuroscience 1995b; 67: 777-90.
30. Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, et al. Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci 2002; 18: 15-27.
31. Blake, AD, Badway, AC, Strowski, MZ. Delineating somatostatin's neuronal actions. Current Drug Tagets-CNS & Neurological Disorders 2004; 3:153-160.
32. Tallent M, Liapakis G, O'Carroll AM, Lolait SJ, Dichter M, Reisine T. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20. Neuroscience 1996; 71: 1073-81.
33. Rohrer SP, Birzin ET, Mosely R, Berk S, Hutchins S, Shen D-M, et al. Integration of high throughput screening and combinatorial chemistry for rapid identification of somatostatin receptor subtype selective analogs. Science 1998; 282: 737-40.
34. Parmar RP, Chan WW-S, Dashkevicz M, Rohrer SP, Smith RG, Schaeffer JM, et al. Nonpeptidyl somatostatin agonists demonstrate that sst2 and sst5 inhibit stimulated growth hormone release from rat anterior pituitary cells. Bioch Biophys Res Comm 1998; 263: 276-80.
35. 1-subtype-selective nonpeptidyl agonist. Neuropharmacology 2001; 40: 590-6.
36. Strowski MZ, Dashkevicz MP, Parmar RM, Wilkinson H, Kohler M, Schaeffer JM, et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 2002; 75: 339-46.
37. Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, et al. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 2003; 17:93-106.
38. Spoerri PE, Caballero S, Wilson SH, Shaw LC, Grant MB. Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Invest Ophthalmol Vis Sci 2003; 44: 365-9.
39. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003; 144: 1574-84.
40. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Rev 2003; 2: 999-1017.
41. Hay BA, Cole BM, DiCapua F, Kirk GW, Murray MC, Nardone RA, et al. Small molecule somatostatin receptor subtype-2 antagonists. Bioorg Med Chem Lett 2001; 11: 2731-4.
42. Poitout L, Roubert P, Contour-Galcera MO, Moinet C, Lannoy J, Pommier J, et al. Identification of potent non-peptide somatostatin antagonists with sst3 selectivity. J Med Chem 2001; 44: 2990-3000.
43. Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, et al. SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci Lett 2004; 361: 132-5.
44. Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AMJ. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol 2000; 278: H1815-22.
45. Feniuk W, Dimech J, Humphrey PP. Characterization of somatostatin receptors in guinea-pig isolated ileum, vas deferens and right atrium. Br J Pharmacol 1993; 110: 1156-64.
46. Feniuk W, Dimech J, Jarvie EM, Humphrey PP. Further evidence from functional studies for somatostatin receptor heterogeneity in guinea-pig isolated ileum, vas deferens and right atrium. Br J Pharmacol 1995; 115: 975-80.
47. Dimech J, Feniuk W, Latimer WD, Humphrey PP. Somatostatin-induced contraction of human isolated saphenous vein involves sst2 receptor-mediated activation of L-type calcium channels. J Cardiovasc Pharmacol 1995; 26: 721-8.
48. Preston E, Courtice GP. Vagal stimulation and somatostatin potentiate cardiac vagal action in the toad, Bufo marinus. Neurosci Lett 1992; 139: 285-8.
49. Day SM, Gu J, Polak JM, Bloom SR. Somatostatin in the human heart and comparison with guinea pig and rat heart. Br Heart J 1985; 53: 153-7.
50. Webb SC, Krikler DM, Hendry WG, Adrian TE, Bloom SR. Electrophysiological actions of somatostatin on the atrioventricular junction in sinus rhythm and reentry tachycardia. Br Heart J 1986; 56: 236-41.
51. Lombardi G, Colao A, Ferone D, Marzullo P, Landi ML, Longobardi S, et al. Cardiovascular aspects in acromegaly: effects of treatment. Metabolism 1996; 45: 57-60.
52. Merola B, Cittadini A, Colao A, Ferone D, Fazio S, Sabatini D, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993; 77: 790-3.
53. Manelli F, Desenzani P, Boni E, Bugari G, Negrini F, Romanelli G, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999; 2: 205-10.
54. Leszczynski D, Zhao Y, Cathapermal SS, Nilsson J, Foegh ML. Rat heart smooth muscle cells express high and low affinity rceptors for somatostatin-14, which are involved in regulation of cell proliferation. Life Sci 1993; 53: 1663-74.
55. Lauder H, Sellers LA, Fan TP, Feniuk W, Humphrey PP. Somatostatin sst5 inhibition of receptor mediated regeneration of rat aortic vascular smooth muscle cells. Br J Pharmacol 1997; 122: 663-70.
56. Curtis SB, Chen JC, Winkelaar G, Turnbull RG, Hewitt J, Buchan AM, et al. Effect of endothelial and advential injury on somatostatin receptor expression. Surgery 2000a; 127: 577-83.
57. Ruiz E, Del Rio M, Tejerina T. Effect of somatostatin on resistance and on capacitance rabbit isolated arteries. Eur J Pharmacol 2000; 388: 255-61.
58. Torrecillas G, Medina J, Diez-Marques ML, Rodriguez-Puyol D, Rodriguez-Puyol M. Mechanisms involved in the somatostatin-induced contraction of vascular smooth muscle cells. Peptides 1999; 20: 929-35.
59. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996; 45: 49-50.
60. Khare S, Kumar U, Sasi R, Puebla L, Calderon L, Lemstrom K, et al. Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty. FASEB J 1999; 13: 387-94.
61. Santoian ED, Schneider JE, Gravanis MB, Foegh M, Tarazona N, Cipolla GD, et al. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Circulation 1993; 88: 11-4.
62. Yamashita M, Dimayuga P, Kaul S, Shah PK, Regnstrom J, Nilsson J, et al. Phosphatase activity in the arterial wall after balloon injury: effect of somatostatin analog octreotide. Lab Invest 1999; 79: 935-44.
63. Schiller NK, Timothy AM, Aurora HS, Chen IL, Coy DH, Murphy WA, et al. A selective somatostatin type-2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following aortic balloon injury in the rabbit. Mol Cell Biochem 2002; 240: 31-7.
64. Alderton F, Lauder H, Feniuk W, Fan T-PD, Humphrey PPA. Differential effects of somatostatin and angiopeptin on cell proliferation. Brit J Pharmacol 1998; 124: 323-30.
65. Emanuelsson H, Beatt KJ, Bagger JP, Balcon R, Heikkila J, Piessens J, et al. Long-term effects of angiopeptin treatment in coronary angioplasty: Reduction of clinical events but not angiographic restenosis: European Angiopeptin Study Group. Circulation 1995; 91: 1689-96.
66. Eriksen UJ, Amtorp O, Bagger JP, Emanuelsson H, Foegh M, Henningsen P, et al. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J 1995; 130: 1-8.
67. Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 2002; 146: 303-9.
68. Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001; 85: 266-72.
69. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
70. Jia WD, Xu GL, Sun HC, Wang L, Xu RN, Xue Q. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo . Hepatobiliary Pancreat Dis Int 2003; 2: 404-9.
71. Gargiulo P, Giusti C, Ietrobono D, La Torre D, Diacono D, Tamburrano G. Diabetes mellitus and retinopathy. Dig Liver Dis 2004; 36: S101-5.
72. Spraul CW, Baldysiak-Figiel A, Lang GK, Lang GE. Octreotide inhibits growth factor-induced bovine choriocapillar endothelial cells in vitro. Graefes Arch Clin Exp Ophthalmol 2002; 240: 227-31.
73. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 2003; 18: 601-9.
74. Weckbecker G, Raulf F, Bodmer D, Bruns C. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Yale J Biol Med 1997; 70: 549-54.
75. Wilson SH, Davis MI, Caballer S, Grant MB. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogs: implications for diabetic retinopathy. Growth Horm IGF Res 2001; 11: S53-9.
76. Florio T, Thellung S, Arena S, Corsaro A, Bajetto A, Schettini G, et al. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol 2000; 94: 239-50.
77. Meyerhof, W. The elucidation of somatostatin receptor functions: a current view. Rev Physiol Biochem Pharmacol 1998; 133: 55-108.
78. Florio T, Scorizello A, Fattore M, D'Alto V, Salzano S, Rossi G, et al. Somatostatin inhibits PC CI3 thyroid cell proliferation through the modulation of phosphotyrosine phosphatase activity - impairment of the somatostatinergic effects by stable expression of EIA viral oncogene. J Biol Chem 1996; 271: 6129-36.
79. Florio T, Arena S, Thellung S, Iuliano R, Corsaro A, Massa A, et al. The activation of the phosphotyrosine phosphatase-η (r-PTPη) is responsible for the somatostatin inhibition of PC CI3 thyroid cell proliferation. Mol Endocrinol 2001; 15: 1838-52.
80. Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carroll AM, Schally A, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA 1997; 94: 9343-8.
81. Held-Feindt J, Forstreuter F, Pufe T, Mentlein R. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Mol Brain Res 2001; 87: 12-21.
82. Dezsi L, Szentivanyi M, Dorney G, Lowenstein L, Farago M, Tulassy T, et al. Regional differences in nitric oxide-dependent vascular responses to somatostatin. Physiol Res 1996; 45: 291-6.
83. Clemens A, Klevesath MS, Hofmann M, Faulf F, Henkels M, Amiral J, et al. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism 1999; 48: 1236-40.
84. Buchan AM, Lin CY, Choi J, Barber DL. Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration. J Biol Chem 2002; 277: 28431-8.
85. Elliott DE, Blum AM, Li J, Metwali A, Weinstock JV. Preprosomatostatin messenger RNA is expressed by inflammatory cells and induced by inflammatory mediators and cytokines. J Immunol 1998; 160:3997-4003.
86. Karalis K, Mastorakos G, Chrousos GP, Tollis G. Somatostatin analogs suppress the inflammatory reactions in vivo. J Clin Invest 1994; 93: 2000-6.
87. Fioravanti A, Govoni M, La Montagna G, Perpignano G, Tirri G, Trotta F, et al. Somatostatin 14 and joint inflammation: evidence for intraarticular efficacy of prolonged administration in rheumatoid arthritis. Drugs Exp Clin Res 1995; 21: 97-103.
88. Elhassan AM, Adem A, Papadogiannakis N, Suliman I, Gad A, Lindgren JU. Intracerebroventricular administration of somatostatin prevents and attenuates adjuvant arthritis. J Neuroimmunol 2001; 116: 15-20.
89. Bellocq A, Doublier S, Suberville S, Perez J, Escoubet B, Fouqueray B, et al. Somatostatin increases glucocorticoid binding and signaling in macrophages by blocking calpain-specific cleavage of hsp 90. J Biol Chem 1999; 274: 36891-6.
90. Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-γ release. Eur J Immunol 1999; 29: 2454-63.
91. Peluso G, Petillo O, Melone MA, Mazzarella G, Ranieri M, Tajana GF. Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 1996; 30: 443-51.
92. Zetter B. The endothelial cells of large and small blood vessels. Diabetes 1981; 30: 24-8.
93. Belloni PN, Nicholson GL. Differential expression of cell surface glycoproteins on various organ-derived microvascular endothelia and endothelial cell cultures. J Cell Physiol 1988; 136: 389-98.
94. Rajotte D, Arap W, Hagedorn M Koivenen E, Pasqualini R, Rusolahti E. Molecular heterogeneity of the vascular endothelium revealed by in vitro phage display. J Clin Invest 1998; 102: 430-7.
95. Vercellotti GM, Dobson M, Schroer AE, Moldow CF. Endothelial cell heterogeneity: antioxidant profiles determine vulnerability to oxidant injury. Proc Soc Exp Biol Med 1988; 187: 181-9.
96. Aavik E, Luoto NM, Petrov L, Aavik. S, Patel YC, Hayry P. Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist. FASEB J 2002; 16: 724-6.
97. Chen JC, Hsiang YN, Buchan AM. Somatostatin receptor expression in rat iliac arteries after balloon injury. J Invest Surg 1997; 10: 17-23.